# FLAURA (NCT02296125)

> AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02296125
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions: AZD9291 80 mg/40 mg + placebo; Placebo Erlotinib 150/100mg; Placebo Gefitinib 250 mg; Erlotinib 150/100 mg; Gefitinib 250 mg; Placebo AZD9291 80 mg/ 40 mg
- Enrollment: 674
- Primary outcome: Median Progression Free Survival (PFS) (Months)
- Primary outcome: Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months

## Commentary we found

- X threads: 89
- Podcasts: 40
- YouTube: 38

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=flaura-nct02296125

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02296125", "email": "<work email>"}; the inbox owner confirms by the emailed link.